
Pharma's Richest Ride Demand Tailwinds
The stellar run continues post-Covid as promoters reap benefits of growth in India and new launches in key markets.
The stellar run continues post-Covid as promoters reap benefits of growth in India and new launches in key markets.
The revenue witnessed 29% growth at ₹6,738.4 crore in the Q1 of FY24, against ₹5,215.4 crore YoY, driven by sales in North America, emerging markets and Europe.
The pharma major received “zero observations” post the USFDA pre-approval inspection (PAI) and a routine GMP inspection at the Andhra Pradesh facility
India’s life sciences R&D is undergoing a sea change. Given the huge risks and investments involved, can India taste success in innovative medicine, therapy and diagnostic tools?
Dr. Reddy's posted a consolidated net profit of ₹1,187.6 crore in Q1FY23, registering a yearly growth of 108.05% and 1,257.25% on a quarterly basis.
Torrent Pharma will acquire Styptovit-E, Finast, Finast-T, and Dynapress brands from Dr Reddy’s Laboratories.
Revenue of the pharma company rose 15% year-on-year to ₹5,437 crore in the fourth quarter.
The BSE Sensex ended 296 points higher at 57,420, and the NSE Nifty surged 82.5 points, led by Tech Mahindra, Dr. Reddy's, Power Grid, and Sun Pharma.
Almost every major Indian pharmaceutical company, including Cipla, Dr Reddy’s, Sun Pharma and Biocon, are on the list of companies which can produce mRNA Covid-19 vaccines
Structural changes in the global pharma industry are throwing up challenges and opportunities. Enter Cipla with its expertise in medicine, and vision for relevance beyond pharma.